BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27973462)

  • 1. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Marušić M; Dominković L; Majstorović Barać K; Gulić S; Bago J; Pezerović D
    Minerva Gastroenterol Dietol; 2017 Jun; 63(2):80-84. PubMed ID: 27973462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J; Pevec B; Tomić M; Marusić M; Bakula V; Bago P
    Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
    Ciccaglione AF; Cellini L; Grossi L; Marzio L
    World J Gastroenterol; 2012 Aug; 18(32):4386-90. PubMed ID: 22969203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
    Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
    Boixeda D; Bermejo F; Martín-De-Argila C; López-Sanromán A; Defarges V; Hernández-Ranz F; Milicua JM; García-Plaza A
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1457-60. PubMed ID: 12182745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
    Kim JY; Lee SY; Kim JH; Sung IK; Park HS
    Helicobacter; 2020 Apr; 25(2):e12683. PubMed ID: 32074663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
    Chung KH; Lee DH; Jin E; Cho Y; Seo JY; Kim N; Jeong SH; Kim JW; Hwang JH; Shin CM
    Gut Liver; 2014 Nov; 8(6):605-11. PubMed ID: 25368747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
    Buzás GM; Széles I
    J Gastroenterol; 2008; 43(2):108-14. PubMed ID: 18306984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
    Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
    Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
    Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
    Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.